ReviewHeliyon2021
Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19.
Review in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Fourth dose of microneedle array patch of SARS-CoV-2 S1 protein subunit vaccine elicits robust long-lasting humoral responses in mice.International immunopharmacology · 2024Article
- Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon.Scientific reports · 2023Article
- The COVID-19 experience in Africa and the Middle East.Annals of medicine · 2023Review
- Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.Journal of Taibah University Medical Sciences · 2023Review
- Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines.Antibodies (Basel, Switzerland) · 2022Review
- Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea.Journal of medical virology · 2022Article
- Coronavirus Disease Update on Epidemiology, Virology, and Prevention.Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995) · 2021Review
- COVID-19: Are reinfections a global health threat?Nepal journal of epidemiology · 2021Article
- Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?Frontiers in medicine · 2021Article
Corrections and comments
- Retraction · 2025-09-06Concerns/Issues about Authorship/Affiliation · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several months after the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), cases of re-infection after recovery were reported. The extent and duration of protective immunity after SARS-CoV-2 infection is not fully understood. As such, the possibility of re-infection with SARS-CoV-2. Furthermore, cases of re-infection were mainly due to different variants or mutant SARS-CoV-2. Following the fast and pandemic-scale spread of COVID-19, mutations in SARS-CoV-2 have raised new diagnostic challenges which include the redesign of the oligonucleotide sequences used in RT-PCR assays to avoid potential primer-sample mismatches, and decrease sensitivities. Since the initial wave of the pandemic, some regions had experienced fresh outbreaks, predisposing people to be susceptible to SARS-CoV-2 re-infection. Hence, this article sought to offer detailed biology of SARS-CoV-2 re-infections and their implications on immune response milieu, diagnostic laboratory tests and control measures against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.